Electronically modified single wall carbon nanohorns with iodine adsorption

Tailoring electronic properties of single wall carbon nanohorn (SWCNH) is expected to develop the application potential in various fields. SWCNH is efficiently modified with iodine molecules by liquid phase adsorption. The adsorption isotherm of iodine on SWCNH was Langmuirian with the saturated adsorption amount of 185 +/- 10 mg g (1) (coverage 0.18), indicating a specific interaction between SWCNH and iodine. The DC electrical conductivity of SWCNH film prepared by dip-coating method increased with the iodine adsorption amount almost by a factor 10.ArticleCHEMICAL PHYSICS LETTERS. 501(4-6):485-490 (2011)journal articl

Raman Doping Profiles of Polyelectrolyte SWNTs in Solution

We present a resonance Raman study of electrochemical charge transfer doping on polyelectrolyte single-walled carbon nanotubes (SWNTs) in solution. Changes in the intensity of the radial breathing modes of well-identified SWNTs are measured as a function of the electrochemical potential. The intensity is maximum when the nanotubes are neutral. Unexpectedly, the Raman signal decreases as soon as charges are transferred to the nanotubes, leading to intensity profiles that are triangular for metallic and trapezoidal for semiconducting nanotubes. A key result is that the width in energy of the plateaus for the semiconducting nanotubes is roughly equal to the optical gap (rather than the free carrier gap). While these experiments can be used to estimate the energy levels of individual nanotubes, strong dynamical screening appears to dominate in individual SWNT polyelectrolytes so that only screened energy levels are being probed

Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis

Despite other TKIs have been approved for frontline CML treatment, imatinib (IM) is an important therapeutic option. Response criteria at given time points have been proposed by the ELN panel, irrespectively of the first-line TKI used, to decide when the treatment should be continued, optimal response (OR), or changed, failure (F); warning (W) is an intermediate zone. To investigate the significance of 2013 ELN response criteria in CML treated frontline with IM, 559 patients enrolled within 3 prospective studies (CML021-022-023) were analyzed (ITT population of each study). ELN criteria at 3 months: not fully evaluable due to missing cytogenetic analysis in 452/559 patients; we focused on the early molecular response (EMR, BCR-ABL <10% at 3 months, corresponding to OR). ELN criteria at 6 and 12 months: F, BCR-ABL >10% and/or Ph+ >35% at 6 months, BCR-ABL >1% and/or Ph+ >0 at 12 months; OR, BCR-ABL <1% and/or Ph+ 0 at 6 months, BCR-ABL <0.1% at 12 months; W: intermediate conditions. Progression: according to 2013 ELN criteria. Molecular response: according to 2015 EUTOS recommendations. Leukemia-unrelated death (LRD): known cause of death, no progression, CCyR or MMR <6 months prior to death; all other deaths were classified as leukemia-related. Median follow-up, 76 (66-99) months. The EMR rate was 82%. The progression-free survival (PFS) and the probability of LRD according to the presence-absence of EMR were 91%-87% (p=0.035) and 11%-5% (p=0.019), respectively. Combining Sokal score and EMR, the patients were divided into 4 groups, LR-IR resp, LR-IR not resp, HR resp, HR not resp: the probability of LRD was 3%-9%-10%-20% (p<0.001). The patients remaining on IM according to the response at 6 months (OR-W-F) were 77%-52%-26%, respectively. The PFS and the probability of LRD according to ELN response at 6 months (OR-W-F) were 93%-92%-77% (p<0.001) and 2%-5%-28% (p<0.001), respectively. The patients remaining on IM according to the response at 12 months (OR-W-F) were 80%-72%-35%, respectively. The PFS and the probability of LRD according to ELN response criteria at 12 months (OR-W-F) were 95%-96%-85% (p<0.001) and 1%-1%- 16% (p<0.001), respectively. Patients without OR at 3 months (particularly high risk patients) had poorer outcome compared to patients with OR. Patients classified as W at 6 and 12 months have similar outcome to OR patients, both significantly better than F. The subsequent treatment may explain, at least in part, the absence of differences

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia

First-line nilotinib in chronic myeloid leukemia is more effective than imatinib to achieve early and deep molecular responses, despite poor tolerability or failure observed in one-third of patients. The toxicity and efficacy of tyrosine kinase inhibitors might depend on the activity of transmembrane transporters. However, the impact of transporters genes polymorphisms in nilotinib setting is still debated. We investigated the possible correlation between single nucleotide polymorphisms of hOCT1 (rs683369 [c.480C > G]) and ABCB1 (rs1128503 [c.1236C > T], rs2032582 [c.2677G > T/A], rs1045642 [c.3435C > T]) and nilotinib efficacy and toxicity in a cohort of 78 patients affected by chronic myeloid leukemia in the context of current clinical practice. The early molecular response was achieved by 81% of patients while 64% of them attained deep molecular response (median time, 26 months). The 36-month event-free survival was 86%, whereas 58% of patients experienced toxicities. Interestingly, hOCT1 and ABCB1 polymorphisms alone or in combination did not influence event-free survival or the adverse events rate. Therefore, in contrast to data obtained in patients treated with imatinib, hOCT1 and ABCB1 polymorphisms do not impact on nilotinib efficacy or toxicity. This could be relevant in the choice of the first-line therapy: patients with polymorphisms that negatively condition imatinib efficacy might thus receive nilotinib as first-line therapy

Efficacy and safety of low-dose aspirin in polycythemia vera

BACKGROUND: The use of aspirin for the prevention of thrombotic complications in polycythemia vera is controversial. METHODS: We enrolled 518 patients with polycythemia vera, no clear indication for aspirin treatment, and no contraindication to such treatment in a double-blind, placebo-controlled, randomized trial to assess the safety and efficacy of prophylaxis with low-dose aspirin (100 mg daily). The two primary end points were the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and the cumulative rate of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes. The mean duration of follow-up was about three years. RESULTS: Treatment with aspirin, as compared with placebo, reduced the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes (relative risk, 0.41; 95 percent confidence interval, 0.15 to 1.15; P=0.09) and the risk of the combined end point of nonfatal myocardial infarction, nonfatal stroke, pulmonary embolism, major venous thrombosis, or death from cardiovascular causes (relative risk, 0.40; 95 percent confidence interval, 0.18 to 0.91; P=0.03). Overall mortality and cardiovascular mortality were not reduced significantly. The incidence of major bleeding episodes was not significantly increased in the aspirin group (relative risk, 1.62; 95 percent confidence interval, 0.27 to 9.71). CONCLUSIONS: Low-dose aspirin can safely prevent thrombotic complications in patients with polycythemia vera who have no contraindications to such treatment